Amicar
(Aminocaproic Acid)Phase 1Small molecule
Amicar is one of 59 small molecule programs targeting Hematoma. It is currently in Phase 1.
2
Indications
7
Total Trials
0
Active Trials
58
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
88 competitors in Intracerebral Hemorrhage
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsPhase 3
Activase
RochePhase 3
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Statin
Bristol-Myers SquibbPhase 3
Olumiant
Eli LillyPhase 2
Crestor
AstraZenecaPhase 2
Actos
TakedaPhase 2
Tecfidera
BiogenPhase 2
Minocycline /d
UUniversity of Florida
Phase 3
Celebrex
PPhiladelphia Eye Associates
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cardiac Surgery1 trial
Non-Opioid Pain Management1 trial
Intracerebral Hemorrhage1 trial
2 more indications
Clinical Trial1 trial
Randomized Clinical Trial With Aminocaproic Acid in the Prevention of Exodontic Bleeding in Anticoagulants Patients
Unknown status·GGrupo de Estudos Multicentricos em Onco-Hematologia·Phase 4·NCT02238288·154 enrolled
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
AMICAR
NDA NDA015229
Jan 1, 1982
AMICAR
NDA NDA015230
Oct 29, 1982
AMINOCAPROIC ACID
NDA NDA018590
Jun 24, 2004
AMICAR
NDA NDA015197
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aminocaproic Acid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- HHikma Pharmaceuticals LLC